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The title compound, C12H18N4O2, crystallizes in the zwitter-
ionic form with protonation at the N atom of the piperazine
ring bearing the carboxylate group. The piperazine ring adopts
a slightly distorted chair conformation. In the crystal, N—
H  O hydrogen bonds are observed, forming chains along
[010]. The packing is consolidated by C—H  O interactions,
which generate a three-dimensional network.
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1. Related literature
For general background and pharmacological properties of
fused heterocyclic derivatives, see: Amin et al. (2009); Ibrahim
& El-Metwally (2010); Kuyper et al. (1996); Onal & Yıldırım
(2007); Padmaja et al. (2009); Tollefson et al. (1991). For
pharmacological properties of pyrimidines, see: Burdge
(2000). For background to aza-Michael reactions, see: Arend
et al.(1998); Vicario et al. (2005); Xu & Xia (2005). For related




C12H18N4O2 Mr = 250.30
Monoclinic, P21=c
a = 13.5157 (6) A˚
b = 7.8454 (3) A˚
c = 12.2147 (5) A˚
 = 106.884 (5)
V = 1239.36 (9) A˚3
Z = 4
Cu K radiation
 = 0.77 mm1
T = 173 K
0.32  0.22  0.06 mm
2.2. Data collection
Agilent Eos Gemini diffractometer
Absorption correction: multi-scan
(CrysAlis PRO and CrysAlis
RED; Agilent, 2012)
Tmin = 0.854, Tmax = 1.000
3995 measured reflections
3995 independent reflections
3668 reflections with I > 2(I)
2.3. Refinement
R[F 2 > 2(F 2)] = 0.053




H atoms treated by a mixture of
independent and constrained
refinement
max = 0.36 e A˚
3
min = 0.27 e A˚3
Table 1
Hydrogen-bond geometry (A˚, ).
D—H  A D—H H  A D  A D—H  A
N1—H1  O2i 1.00 1.67 2.653 (2) 168
C2—H2B  O2i 0.99 2.51 3.277 (3) 134
C4—H4B  O1ii 0.99 2.58 3.428 (3) 144
C7—H7B  O1i 0.99 2.53 3.147 (3) 120
C11—H11  O1iii 0.95 2.47 3.352 (3) 155
Symmetry codes: (i) x; y 12;zþ 12; (ii) x;yþ 1;zþ 1; (iii)
x þ 1;yþ 12; zþ 12.
Data collection: CrysAlis PRO (Agilent, 2012); cell refinement:
CrysAlis PRO; data reduction: CrysAlis RED; program(s) used to
solve structure: SUPERFLIP (Palatinus & Chapuis, 2007);
program(s) used to refine structure: SHELXL2012 (Sheldrick, 2008);
molecular graphics: OLEX2 (Dolomanov et al., 2009); software used
to prepare material for publication: OLEX2.
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Crystal structure of 3-[4-(pyrimidin-2-yl)piperazin-1-ium-1-yl]butanoate
Thammarse S. Yamuna, Jerry P. Jasinski, Manpreet Kaur, Brian J. Anderson and H.S. Yathirajan
S1. Comment 
Pyrimidines in general have been of much interest for biological and medical reasons and thus their chemistry has been 
investigated extensively (Onal & Yıldırım, 2007) and in many drugs used for the treatment of hypothyroidism and 
hypertension, in cancer chemotherapy or HIV infections (Burdge, 2000) and with related fused heterocyclic compounds 
that exhibit biological activities such as anticancer (Amin et al., 2009), antiviral (Ibrahim & El-Metwally, 2010), 
antibacterial (Kuyper et al., 1996) and antioxidant (Padmaja et al., 2009). Some pyrimidinylpiperazinyl compounds like 
buspirone and BuSpar (Tollefson et al., 1991) are used to treat anxiety. The incorporation of two moieties increases 
biological activity of both the molecules. Aza-Michael addition reaction has been extensively studied using a variety of 
catalysts as well as solvents and various researchers have also reported the utility of aza-Michael addition towards the 
synthesis of various pharmacological active compounds and proved useful in the synthesis of core intermediates of many 
natural products (Arend et al., 1998). The role of aza-Michael reaction in the synthesis of pharmacologically important 
families of β-amino carbonyl compounds and its derivatives is well documented in the literature (Vicario et al., 2005; Xu 
& Xia, 2005). Our research group has published many papers on incorporated heterocyclic ring structures, viz; 
4-(pyrimidin-2-yl)piperazin-1-ium (E)-3-carboxyprop-2-enoate (Yamuna et al., 2014a); flupentixol tartarate (Yamuna et 
al., 2014b). Some related zwitterion structures are: 3,3′-(piperazine-1,4-diium-1,4-diyl)dipropionate dihydrate (Jin et al., 
2012), enoxacin trihydrate[1-ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(piperazin-4-ium-1-yl)-1,8- naphthyridine-3-carboxylate 
trihydrate] (Parvez et al., 2004). In view of the importance of derivatives of the incorporated heterocyclic 
pyrimidylpiperazines, this paper reports the crystal structure of the title zwitterionic compound, (I), 3-(4-Pyrimidin-2-yl-
piperazin-1-ium-1-yl)-butanoate, C12H18N4O2 prepared from 2-(piperazin-1-yl)pyrimidine and but-2-enoic acid by aza-
Michael addition reaction.
The title compound, (I), C12H18N4O2 crystallizes in the zwitterionic form with protonation on the N1 nitrogen atom of 
the piperazine ring (Fig. 1). In the compound, the piperazine ring adopts a slightly disordered chair conformation 
(puckering parameters Q, θ, and φ = 0.576 (2)Å, 3.0 (2)° and 282 (4)°, respectively. Bond lengths are in normal ranges. In 
the crystal, N—H···O intermolecular hydrogen bonds are observed forming 1D chains along [0 1 0] (Fig. 2). The packing 
is consolidated by weak C—H···O interactions which generate a three-dimensional network.
S2. Experimental 
A mixture of 1-(2-pyrimidyl)piperazine, from sigma-aldrich (0.2 g, 1.22 mmol) and crotonic acid (but-2-enoic acid) 
(0.1048 g, 1.22 mmol ) were dissolved in DMSO, stirred well and warmed at 343 K for 20 minutes. After few days, X-
ray quality crystals were obtained on slow evaporation (m.p.: 411-418 K).
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S3. Refinement 
H3 was refined isotropically and all of the remaining H atoms were placed in their calculated positions and then refined 
using the riding model with Atom—H lengths of 0.95Å (CH); 0.99Å (CH2); 0.98Å (CH3) or 1.00Å (NH). Isotropic 
displacement parameters for these atoms were set to 1.2 (CH, CH2, NH) or 1.5 (CH3) times Ueq of the parent atom. 
Idealised Me was refined as a rotating group. The title compound was refined as a twin with BASF = 0.41572.
Figure 1
ORTEP drawing of (C12H18N4O2) showing the labeling scheme of the asymmetric unit of the title compound with 30% 
probability displacement ellipsoids. 
supporting information
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Figure 2
Molecular packing for (I), viewed along the b axis. Dashed lines indicate weak C—H···O intermolecular interactions in 
addition to N—H···O intermolecular hydrogen bonds which together form an extended three-dimensional supramolecular 






a = 13.5157 (6) Å
b = 7.8454 (3) Å
c = 12.2147 (5) Å
β = 106.884 (5)°
V = 1239.36 (9) Å3
Z = 4
F(000) = 536
Dx = 1.341 Mg m−3
Cu Kα radiation, λ = 1.54184 Å
Cell parameters from 5404 reflections
θ = 3.8–71.4°
µ = 0.77 mm−1
T = 173 K
Irregular, colourless
0.32 × 0.22 × 0.06 mm
Data collection 
Agilent Eos Gemini 
diffractometer
Radiation source: Enhance (Cu) X-ray Source
Detector resolution: 16.0416 pixels mm-1
ω scans
Absorption correction: multi-scan 
(CrysAlis PRO and CrysAlis RED; Agilent, 
2012)
Tmin = 0.854, Tmax = 1.000
3995 measured reflections
3995 independent reflections
3668 reflections with I > 2σ(I)















Primary atom site location: structure-invariant 
direct methods
Hydrogen site location: mixed
H atoms treated by a mixture of independent 
and constrained refinement
w = 1/[σ2(Fo2) + (0.0768P)2 + 0.6386P] 
where P = (Fo2 + 2Fc2)/3
(Δ/σ)max < 0.001
Δρmax = 0.36 e Å−3
Δρmin = −0.27 e Å−3
Special details 
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance 
matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; 
correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate 
(isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refined as a 2-component twin.
Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2) 
x y z Uiso*/Ueq
O1 −0.15848 (13) 0.4680 (3) 0.29107 (16) 0.0449 (5)
O2 −0.05978 (12) 0.4109 (2) 0.17822 (15) 0.0339 (4)
N1 0.16438 (12) 0.1694 (2) 0.44116 (14) 0.0217 (4)
H1 0.1313 0.0618 0.4040 0.026*
N2 0.32869 (12) 0.0043 (3) 0.60849 (16) 0.0287 (4)
N3 0.40034 (14) 0.0836 (3) 0.79721 (17) 0.0324 (5)
N4 0.50457 (13) 0.0549 (3) 0.66957 (17) 0.0336 (5)
C1 −0.08258 (15) 0.4025 (3) 0.2726 (2) 0.0277 (5)
C2 −0.00940 (16) 0.2979 (3) 0.3691 (2) 0.0308 (5)
H2A −0.0174 0.3357 0.4434 0.037*
H2B −0.0296 0.1763 0.3588 0.037*
C3 0.10322 (15) 0.3150 (3) 0.3722 (2) 0.0260 (5)
H3 0.098 (2) 0.289 (4) 0.289 (3) 0.041 (8)*
C4 0.16425 (15) 0.1604 (3) 0.56333 (18) 0.0261 (5)
H4A 0.0922 0.1532 0.5671 0.031*
H4B 0.1959 0.2650 0.6040 0.031*
C5 0.22479 (15) 0.0048 (3) 0.6211 (2) 0.0290 (5)
H5A 0.2291 0.0053 0.7034 0.035*
H5B 0.1880 −0.1001 0.5866 0.035*
C6 0.32772 (15) 0.0092 (3) 0.48941 (19) 0.0276 (5)
H6A 0.2918 −0.0928 0.4491 0.033*
H6B 0.3995 0.0084 0.4845 0.033*
C7 0.27285 (14) 0.1685 (3) 0.43312 (18) 0.0243 (4)
H7A 0.3102 0.2707 0.4716 0.029*
H7B 0.2719 0.1716 0.3518 0.029*
C8 0.41389 (15) 0.0508 (3) 0.69526 (18) 0.0248 (4)
C9 0.48642 (19) 0.1182 (3) 0.8810 (2) 0.0359 (5)
H9 0.4802 0.1456 0.9545 0.043*
supporting information
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C10 0.58388 (18) 0.1162 (3) 0.8665 (2) 0.0372 (6)
H10 0.6444 0.1349 0.9284 0.045*
C11 0.58837 (17) 0.0857 (3) 0.7574 (2) 0.0376 (6)
H11 0.6540 0.0864 0.7436 0.045*
C12 0.14735 (18) 0.4895 (3) 0.4145 (2) 0.0329 (5)
H12A 0.1545 0.4997 0.4964 0.049*
H12B 0.1007 0.5784 0.3725 0.049*
H12C 0.2153 0.5026 0.4019 0.049*
Atomic displacement parameters (Å2) 
U11 U22 U33 U12 U13 U23
O1 0.0322 (9) 0.0605 (12) 0.0415 (11) 0.0190 (8) 0.0099 (8) 0.0110 (9)
O2 0.0282 (8) 0.0318 (8) 0.0409 (10) 0.0066 (6) 0.0087 (7) 0.0019 (7)
N1 0.0143 (7) 0.0280 (9) 0.0214 (9) 0.0003 (6) 0.0028 (6) 0.0038 (7)
N2 0.0138 (8) 0.0488 (11) 0.0234 (9) 0.0065 (7) 0.0053 (7) 0.0076 (8)
N3 0.0284 (9) 0.0427 (11) 0.0266 (10) 0.0100 (8) 0.0088 (8) 0.0026 (8)
N4 0.0184 (8) 0.0522 (12) 0.0303 (10) 0.0007 (8) 0.0070 (8) −0.0065 (9)
C1 0.0200 (9) 0.0303 (11) 0.0295 (11) −0.0011 (8) 0.0018 (8) 0.0025 (9)
C2 0.0222 (10) 0.0364 (12) 0.0335 (12) 0.0054 (9) 0.0078 (9) 0.0073 (10)
C3 0.0200 (9) 0.0287 (10) 0.0259 (10) 0.0018 (8) 0.0014 (8) 0.0052 (9)
C4 0.0166 (9) 0.0379 (12) 0.0245 (10) 0.0041 (8) 0.0072 (8) 0.0033 (9)
C5 0.0158 (9) 0.0441 (13) 0.0282 (11) 0.0042 (8) 0.0084 (8) 0.0112 (10)
C6 0.0169 (9) 0.0424 (13) 0.0233 (10) 0.0046 (8) 0.0059 (8) 0.0012 (9)
C7 0.0154 (9) 0.0373 (11) 0.0204 (10) −0.0038 (8) 0.0055 (7) 0.0012 (9)
C8 0.0184 (9) 0.0304 (10) 0.0254 (11) 0.0077 (8) 0.0062 (8) 0.0044 (9)
C9 0.0359 (12) 0.0428 (13) 0.0264 (12) 0.0102 (10) 0.0051 (10) −0.0020 (10)
C10 0.0297 (11) 0.0408 (13) 0.0336 (13) 0.0035 (10) −0.0027 (10) −0.0052 (10)
C11 0.0199 (10) 0.0495 (14) 0.0407 (14) 0.0000 (10) 0.0046 (9) −0.0103 (11)
C12 0.0322 (11) 0.0287 (11) 0.0337 (13) −0.0001 (9) 0.0032 (10) 0.0024 (10)
Geometric parameters (Å, º) 
O1—C1 1.226 (3) C4—H4A 0.9900
O2—C1 1.278 (3) C4—H4B 0.9900
N1—H1 1.0000 C4—C5 1.524 (3)
N1—C3 1.514 (2) C5—H5A 0.9900
N1—C4 1.494 (3) C5—H5B 0.9900
N1—C7 1.498 (2) C6—H6A 0.9900
N2—C5 1.457 (2) C6—H6B 0.9900
N2—C6 1.451 (3) C6—C7 1.513 (3)
N2—C8 1.369 (3) C7—H7A 0.9900
N3—C8 1.335 (3) C7—H7B 0.9900
N3—C9 1.335 (3) C9—H9 0.9500
N4—C8 1.351 (3) C9—C10 1.379 (3)
N4—C11 1.336 (3) C10—H10 0.9500
C1—C2 1.538 (3) C10—C11 1.373 (4)
C2—H2A 0.9900 C11—H11 0.9500
supporting information
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C2—H2B 0.9900 C12—H12A 0.9800
C2—C3 1.518 (3) C12—H12B 0.9800
C3—H3 1.01 (3) C12—H12C 0.9800
C3—C12 1.523 (3)
C3—N1—H1 106.5 N2—C5—H5B 109.4
C4—N1—H1 106.5 C4—C5—H5A 109.4
C4—N1—C3 115.63 (17) C4—C5—H5B 109.4
C4—N1—C7 110.51 (15) H5A—C5—H5B 108.0
C7—N1—H1 106.5 N2—C6—H6A 109.7
C7—N1—C3 110.70 (15) N2—C6—H6B 109.7
C6—N2—C5 112.18 (17) N2—C6—C7 109.75 (18)
C8—N2—C5 122.52 (19) H6A—C6—H6B 108.2
C8—N2—C6 121.99 (18) C7—C6—H6A 109.7
C8—N3—C9 115.4 (2) C7—C6—H6B 109.7
C11—N4—C8 115.6 (2) N1—C7—C6 109.51 (16)
O1—C1—O2 125.4 (2) N1—C7—H7A 109.8
O1—C1—C2 118.0 (2) N1—C7—H7B 109.8
O2—C1—C2 116.65 (19) C6—C7—H7A 109.8
C1—C2—H2A 109.0 C6—C7—H7B 109.8
C1—C2—H2B 109.0 H7A—C7—H7B 108.2
H2A—C2—H2B 107.8 N3—C8—N2 117.45 (18)
C3—C2—C1 112.91 (18) N3—C8—N4 126.3 (2)
C3—C2—H2A 109.0 N4—C8—N2 116.26 (19)
C3—C2—H2B 109.0 N3—C9—H9 118.3
N1—C3—C2 109.19 (17) N3—C9—C10 123.5 (2)
N1—C3—H3 105.9 (16) C10—C9—H9 118.3
N1—C3—C12 113.11 (17) C9—C10—H10 122.0
C2—C3—H3 100.5 (16) C11—C10—C9 116.1 (2)
C2—C3—C12 112.28 (19) C11—C10—H10 122.0
C12—C3—H3 115.0 (17) N4—C11—C10 123.0 (2)
N1—C4—H4A 109.6 N4—C11—H11 118.5
N1—C4—H4B 109.6 C10—C11—H11 118.5
N1—C4—C5 110.12 (17) C3—C12—H12A 109.5
H4A—C4—H4B 108.1 C3—C12—H12B 109.5
C5—C4—H4A 109.6 C3—C12—H12C 109.5
C5—C4—H4B 109.6 H12A—C12—H12B 109.5
N2—C5—C4 110.96 (17) H12A—C12—H12C 109.5
N2—C5—H5A 109.4 H12B—C12—H12C 109.5
O1—C1—C2—C3 −144.6 (2) C6—N2—C5—C4 −57.3 (3)
O2—C1—C2—C3 36.8 (3) C6—N2—C8—N3 163.5 (2)
N1—C4—C5—N2 54.5 (2) C6—N2—C8—N4 −18.1 (3)
N2—C6—C7—N1 −59.2 (2) C7—N1—C3—C2 172.41 (18)
N3—C9—C10—C11 3.7 (4) C7—N1—C3—C12 −61.8 (2)
C1—C2—C3—N1 −161.91 (18) C7—N1—C4—C5 −55.5 (2)
C1—C2—C3—C12 71.8 (3) C8—N2—C5—C4 102.5 (2)
C3—N1—C4—C5 177.77 (16) C8—N2—C6—C7 −100.4 (2)
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C3—N1—C7—C6 −172.54 (17) C8—N3—C9—C10 −1.8 (4)
C4—N1—C3—C2 −61.0 (2) C8—N4—C11—C10 −1.8 (4)
C4—N1—C3—C12 64.8 (2) C9—N3—C8—N2 176.1 (2)
C4—N1—C7—C6 58.0 (2) C9—N3—C8—N4 −2.2 (3)
C5—N2—C6—C7 59.5 (2) C9—C10—C11—N4 −1.7 (4)
C5—N2—C8—N3 5.7 (3) C11—N4—C8—N2 −174.3 (2)
C5—N2—C8—N4 −175.9 (2) C11—N4—C8—N3 4.0 (4)
Hydrogen-bond geometry (Å, º) 
D—H···A D—H H···A D···A D—H···A
N1—H1···O2i 1.00 1.67 2.653 (2) 168
C2—H2B···O2i 0.99 2.51 3.277 (3) 134
C4—H4B···O1ii 0.99 2.58 3.428 (3) 144
C7—H7B···O1i 0.99 2.53 3.147 (3) 120
C11—H11···O1iii 0.95 2.47 3.352 (3) 155
Symmetry codes: (i) −x, y−1/2, −z+1/2; (ii) −x, −y+1, −z+1; (iii) x+1, −y+1/2, z+1/2.
